Rallybio Corporation
NASDAQ:RLYB · NASDAQ Capital Market
+$0.01 today
Vol 0.02M · Avg 0.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-15.5%
avg -52.8%
ROIC
-48.3%
avg -57.6%
ROA
-14.4%
avg -46.7%
Analysis
ROA is currently the strongest return metric at -14.4% versus its period average of -46.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephen Uden | Co-Founder, President, Chief Executive Officer & Director | $857,980.00 | — | 68 | $453,700.00 | 7.82% |
Jonathan I. Lieber | Chief Financial Officer & Treasurer | $645,488.00 | — | 56 | $4,115.00 | 0.07% |
Martin W. MacKay | Co-Founder & Chairman | $290,000.00 | — | 70 | $18,055.00 | 0.31% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
14
$4.23M
Sells
1
$3,992.34
Net Sentiment
+$4.23M
Net buying
Most Active
ADAR1 Capital Management, LLC
14 transactions
1–10 of 15
Analysis
Insiders reported 14 buys worth $4.23M and 1 sells worth $3,992.34 over the last 12 months. That adds up to net buying of $4.23M. ADAR1 Capital Management, LLC was the most active insider with 14 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Q32 Bio Inc.
NASDAQ:QTTB
$156.64M
Boundless Bio, Inc.
BOLD
$31.90M
iBio, Inc.
IBIO
$25.97M
Klotho Neurosciences, Inc.
KLTO
$20.08M
Exicure, Inc.
XCUR
$15.81M
TAO Synergies Inc.
TAOX
$12.09M
Cadrenal Therapeutics, Inc. Common Stock
CVKD
$9.39M
Sonnet BioTherapeutics Holdings, Inc.
SONN
$8.43M
Intensity Therapeutics, Inc.
INTS
$7.17M
Iterum Therapeutics plc
ITRM
$1.60M
Who manages RLYB?
Rallybio Corporation (RLYB) lists 3 active executives. The top listed executive is Stephen Uden, Co-Founder, President, Chief Executive Officer & Director.
Are RLYB insiders buying or selling?
Recent insider activity shows net buying of $60.66M.
Explore More
Continue the stock analysis
Jump to another research area for this company.